XTL Biopharmaceutica Financials
| XTLB Stock | USD 1.74 0.08 4.82% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.98 | 8.94 |
|
|
Investors should never underestimate XTL Biopharmaceutica's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor XTL Biopharmaceutica's cash flow, debt, and profitability to make informed and accurate decisions about investing in XTL Biopharmaceuticals Ltd.
Net Income |
|
XTL | Select Account or Indicator |
Understanding current and past XTL Biopharmaceutica Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of XTL Biopharmaceutica's financial statements are interrelated, with each one affecting the others. For example, an increase in XTL Biopharmaceutica's assets may result in an increase in income on the income statement.
Please note, the presentation of XTL Biopharmaceutica's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, XTL Biopharmaceutica's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of XTL Biopharmaceutica's management manipulating its earnings.
XTL Biopharmaceutica Stock Summary
XTL Biopharmaceutica competes with Benitec Biopharma, Xenetic Biosciences, ProPhase Labs, and BOS Better. XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel. Xtl Biopharma is traded on NASDAQ Exchange in the United States.| Foreign Associate | Israel |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US98386D3070 |
| CUSIP | 98386D307 98386D208 98386D109 |
| Location | New York; U.S.A |
| Business Address | 26 Ben-Gurion St, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.xtlbio.com |
| Phone | 972 3 611 6600 |
| Currency | USD - US Dollar |
XTL Biopharmaceutica Key Financial Ratios
| Return On Equity | -0.26 | ||||
| Operating Margin | (16.61) % | ||||
| Price To Sales | 333.39 X | ||||
| Gross Profit | 46 K | ||||
| EBITDA | (764 K) |
XTL Biopharmaceutica Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 6.5M | 6.6M | 4.2M | 2.4M | 2.2M | 2.1M | |
| Total Liab | 254K | 1.3M | 187K | 206K | 185.4K | 176.1K | |
| Other Current Liab | 252K | 229K | 185K | 205K | 184.5K | 175.3K | |
| Other Liab | 1.0M | 465K | 2.6M | 1.1M | 1.2M | 1.3M | |
| Net Debt | (3.6M) | (3.0M) | (2.1M) | (1.4M) | (1.6M) | (1.7M) | |
| Retained Earnings | (154.7M) | (155.1M) | (156.5M) | (158.2M) | (142.4M) | (149.5M) | |
| Cash | 3.6M | 3.0M | 2.1M | 1.4M | 1.3M | 1.2M | |
| Other Current Assets | 79K | 110K | 85K | 40K | 36K | 68K | |
| Total Current Assets | 6.1M | 6.2M | 3.8M | 2.0M | 1.8M | 1.7M | |
| Net Tangible Assets | 6.6M | 3.2M | 5.0M | 3.6M | 4.2M | 4.6M | |
| Net Invested Capital | 6.2M | 5.3M | 4.0M | 2.2M | 2.0M | 1.9M | |
| Net Working Capital | 5.9M | 6.0M | 3.6M | 1.8M | 1.7M | 1.6M |
XTL Biopharmaceutica Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Operating Income | (948K) | (1.0M) | (880K) | (765K) | (879.8K) | (923.7K) | |
| Ebit | (948K) | (1.0M) | (880K) | (765K) | (879.8K) | (923.7K) | |
| Ebitda | (947K) | (1.0M) | (879K) | (764K) | (878.6K) | (922.5K) | |
| Net Income | (782K) | 435K | (1.3M) | (1.8K) | (2.0K) | (2.2K) | |
| Income Tax Expense | (166K) | (1.5M) | 468K | (167.9K) | (151.1K) | (143.5K) | |
| Income Before Tax | (782K) | 435K | (1.3M) | (1.8M) | (2.0M) | (2.2M) | |
| Total Revenue | 52K | 69K | 28K | 1.5M | (459K) | 0.0 | |
| Gross Profit | 69K | 27K | 1.5M | (460K) | (414K) | (393.3K) | |
| Interest Income | 33K | 8K | 36K | 46K | 41.4K | 34.2K | |
| Net Interest Income | 16K | 3K | 25K | (28K) | (25.2K) | (23.9K) |
XTL Biopharmaceutica Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (824K) | (662K) | (875K) | (693K) | (623.7K) | (592.5K) | |
| Free Cash Flow | (851K) | (1.0M) | (901K) | (707K) | (813.1K) | (853.7K) | |
| Other Non Cash Items | (33K) | (8K) | (36K) | 1.0M | 907.2K | 952.6K | |
| Net Income | (782K) | 435K | (1.3M) | (1.8M) | (2.0M) | (2.2M) | |
| End Period Cash Flow | 3.6M | 3.0M | 2.1M | 1.4M | 1.3M | 1.2M | |
| Investments | 32K | 8K | 36K | 41K | 36.9K | 35.1K | |
| Change To Netincome | 489K | (114K) | (1.4M) | 447K | 402.3K | 422.4K |
XTL Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining XTL Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare XTL Biopharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across XTL Biopharmaceutica competition to find correlations between indicators driving XTL Biopharmaceutica's intrinsic value. More Info.XTL Biopharmaceuticals Ltd is rated first in return on equity category among its peers. It is rated first in return on asset category among its peers . At present, XTL Biopharmaceutica's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the XTL Biopharmaceutica's earnings, one of the primary drivers of an investment's value.XTL Biopharmaceuticals Systematic Risk
XTL Biopharmaceutica's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. XTL Biopharmaceutica volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-one with a total number of output elements of fourty. The Beta measures systematic risk based on how returns on XTL Biopharmaceuticals correlated with the market. If Beta is less than 0 XTL Biopharmaceutica generally moves in the opposite direction as compared to the market. If XTL Biopharmaceutica Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one XTL Biopharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of XTL Biopharmaceutica is generally in the same direction as the market. If Beta > 1 XTL Biopharmaceutica moves generally in the same direction as, but more than the movement of the benchmark.
About XTL Biopharmaceutica Financials
What exactly are XTL Biopharmaceutica Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include XTL Biopharmaceutica's income statement, its balance sheet, and the statement of cash flows. Potential XTL Biopharmaceutica investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although XTL Biopharmaceutica investors may use each financial statement separately, they are all related. The changes in XTL Biopharmaceutica's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on XTL Biopharmaceutica's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Today, most investors in XTL Biopharmaceutica Stock are looking for potential investment opportunities by analyzing not only static indicators but also various XTL Biopharmaceutica's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of XTL Biopharmaceutica growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
XTL Biopharmaceutica February 17, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of XTL Biopharmaceutica help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of XTL Biopharmaceuticals Ltd. We use our internally-developed statistical techniques to arrive at the intrinsic value of XTL Biopharmaceuticals Ltd based on widely used predictive technical indicators. In general, we focus on analyzing XTL Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build XTL Biopharmaceutica's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.68 | |||
| Information Ratio | 0.0078 | |||
| Maximum Drawdown | 32.37 | |||
| Value At Risk | (7.22) | |||
| Potential Upside | 9.04 |
Complementary Tools for XTL Stock analysis
When running XTL Biopharmaceutica's price analysis, check to measure XTL Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XTL Biopharmaceutica is operating at the current time. Most of XTL Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of XTL Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XTL Biopharmaceutica's price. Additionally, you may evaluate how the addition of XTL Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |